Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising cocktail targets brain cancer

NCT ID NCT07410520

Recruiting now Disease control Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a combination of four drugs (PD-1 inhibitor, rituximab, methotrexate, and orelabrutinib) in 50 people with newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this mix can stop the cancer from growing for at least a year. Participants will receive the drugs intravenously and orally over several cycles, with maintenance therapy for up to two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
PD-1 inhibitor, rituximab, methotrexate, and orelabrutinib
What this could lead to
If successful, this combination could offer a more effective first-line treatment for central nervous system lymphoma, potentially improving long-term survival and reducing relapse.
What could go wrong
This is a small, early-phase trial (50 participants) with no comparison group, so results may not be definitive. The drug combination can cause serious side effects like infections or organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary central nervous system lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (SCNSL)

Contacts and locations

Locations

  • The First Affiliated Hospital with Nanjing Medical University

    RECRUITING

    Nanjing, Jiangsu, 210029, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.